CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Vanda Pharmaceuticals INC. (VNDA) / tradipitant
Forward catalyst · VNDA

tradipitant

Sponsor Vanda Pharmaceuticals INC. · listed as VNDA

READOUT Phase 3 Confidence: medium Source: clinicaltrials

tradipitant is a drug asset sponsored by Vanda Pharmaceuticals INC., listed as VNDA. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 1, 2026 (day precision, medium confidence), tied to trial NCT07446439. That trial is in Phase 3 and currently recruiting, studying Nausea and Vomiting.

Next catalyst

Event typeREADOUT
Expected date2026-12-01
As disclosedDec 1, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT07446439
PhasePHASE3
StatusRECRUITING
Lead sponsorVanda Pharmaceuticals
Listed asVNDA
Condition(s)Nausea and Vomiting; Obesity
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More VNDA catalysts

Related catalysts and sponsor